NEW DELHI, Feb. 19, 2018 /PRNewswire-USNewswire/
-- Aeras, a nonprofit organization dedicated to developing
vaccines against tuberculosis (TB), will highlight the progress
being made in TB vaccine research at the 5th Global
Forum on TB Vaccines in New Delhi,
India, February 20-23, 2018.
Presentations will include new data from Aeras's advancing
portfolio of TB vaccines, including data from four clinical-stage
candidates.
Ann Ginsberg, MD, PhD, Chief
Medical Officer at Aeras and a member of the organizing committee
for the 5th Global Forum on TB Vaccines, said: "We and
our partners will share a range of new data at the 5th
Global Forum on TB Vaccines, highlighting the scientific progress
being made to develop potential new vaccines against TB, the
world's leading cause of death from an infectious disease."
Over the past decade, more than a dozen new TB vaccine
candidates have been tested in human clinical trials around the
world. Serving as a critical translational bridge from the bench to
the field, Aeras has sponsored and conducted over 55 clinical and
epidemiological studies in 15 different countries. It has worked
with partners to develop new approaches to R&D and new tools,
such as the Controlled Human Infection Model. In addition, Aeras
has contributed to preclinical research efforts by creating
improved animal models of disease to facilitate and enhance initial
screening for promising TB vaccine candidates.
First Data from Innovative Prevention-of-Infection Phase 2
Clinical Trial
Results will be presented for the first time from the Phase 2
prevention-of-infection clinical trial evaluating H4:IC31, a
subunit vaccine candidate, and revaccination with Bacille
Calmette-Guérin (BCG), the world's only commercially available TB
vaccine. The study was conducted to evaluate the safety and
immunogenicity of the vaccine regimens, as well as their ability to
prevent initial and sustained TB infections among healthy
adolescents in the Western Cape Province of South Africa.
Additional Clinical-Stage TB Vaccine Portfolio Data
Data will also be presented on other clinical-stage TB vaccines,
including:
- Data from a Phase 1/2a clinical trial evaluating the safety and
immunogenicity of various dose regimens of H56:IC31 in HIV-negative
adults with and without latent TB infection.
- Follow-up data from a Phase 1 clinical study, evaluating the
ability of the GLA-SE adjuvant to improve the magnitude and quality
of immune response to the ID93 vaccine. This study was the first in
which the ID93 vaccine was tested in humans.
- Data from a Phase 1b trial
evaluating different doses of the ID93+GLA-SE vaccine for use in TB
endemic countries.
- Learnings associated with the impact of implementing an
effective community engagement strategy on retention rates in a
Phase 2b prevention-of-disease study
for the M72 vaccine in South
Africa, Zambia and
Kenya.
Note to Editors
A full list of abstracts associated with research conducted
and/or funded by Aeras to be presented at the 5th Global
Forum on TB Vaccines is as follows:
(Note: All 5th Global Forum presentations and
posters will take place within the Taj Diplomatic Enclave
Hotel (formerly Taj Palace), located at 2 Sardar Patel Marg,
Diplomatic Enclave, New Delhi.
The times provided are in India
Standard Time.)
Abstract #
|
Title
|
Presentation
Details
|
PS-05
|
Enriching cohorts for
smaller, quicker, more
efficient TB vaccine
efficacy trials
|
Plenary Session 1:
Increasing
Probability of
Success and
Maximizing
Impact
Time: 14:00 – 16:00,
February 20
Location:
Shahjehan
|
PD-08
|
Demonstration of a
correlation between the in
vitro direct
mycobacterial growth inhibition
assay (MGIA) and
protection from in vivo
mycobacterial
challenge
|
Poster Discussion 1:
Basic Vaccine
Concepts and
Correlates of
Protective
Immunity
Time 16:15 – 17:45,
February 20
Location:
Roshanara
|
PD-24
|
The ESAT-6 free IGRA,
a companion diagnostic
for ESAT-6 based TB
vaccines
|
Poster Discussion 2:
Diagnostics
and
Epidemiology
Time: 16:15 – 17:45,
February 20
Location: Sheesh
Mahal
|
PD-28
|
Optimization and
interpretation of serial
QuantiFERON testing
to measure acquisition of
M.
tuberculosis infection
|
PA-10
|
Synthetic
Polysaccharide Conjugate Vaccines
Expressing
Mycobacterium tuberculosis Antigens
Induce High-titer
Antibody Responses in Mice,
Guinea Pigs, and
Rabbits
|
Poster Viewing: Novel
Vaccine
Concepts,
Chemistry,
Manufacturing and
Controls
Time: 16:15 – 17:45,
February 20
Location: Mumtaz
Mahal
|
PA-16
|
Comparison of
pellicle and liquid grown BCG
reference strains in
standard BCG batch release
assays and protection
studies
|
PS-06
|
Prevention of
infection with Mycobacterium
tuberculosis
by H4:IC31 vaccination or BCG
revaccination n
healthy adolescents: results of a
randomized controlled
trial
|
Plenary Session 2:
Clinical
Development of New TB
Vaccines
Time: 9:00 – 11:00,
February 21
Location:
Shahjehan
|
PS-10
|
A critical juncture
in tuberculosis vaccine clinical
development:
overview of progress
|
PS-07
|
Community engagement
and Good Participatory
Practice Guidelines
for TB vaccine research and
development
|
OA-09
|
Clinical development
of ID93+GLA-SE as a
prophylactic or
therapeutic vaccine for
tuberculosis
|
Breakout Presentation
2: Clinical
Research
Time: 11:30 – 13:30,
February 21
Location:
Jejangir
|
PS-11
|
The route of BCG
vaccination determines
immunity and
protection against
Mycobacterium
tuberculosis infection in non-
human
primates
|
Plenary Session 3:
Novel
Approaches to TB
Vaccine
Research &
Development
Time: 14:00 – 16:00,
February 21
Location:
Shahjehan
|
PS-12
|
Vaccination following
mycobacterial exposure
|
PD-15
|
T cell immunity in
the lung and protection
following aerosol,
intravenous, or intradermal
administration of BCG
in nonhuman primates
|
Poster Discussion 3:
Preclinical
Research
Time: 16:30 – 18:00,
February 21
Location:
Roshanara
|
PD-14
|
Animal dose response
curve predicts lower
optimal tuberculosis
vaccine dose in humans:
The use of vaccine
Immunostimulation/
Immunodynamic
modelling methods to inform
vaccine dose
decision-making
|
PD-34
|
Immunogenicity of
AERAS-404 or BCG
revaccination in a
prevention of established M.
tuberculosis
infection efficacy trial
|
Poster Discussion 4:
Clinical
Research and
Community
Engagement
Time: 16:30 – 18:00,
February 21
Location: Sheesh
Mahal
|
PD-38
|
Safety and
immunogenicity of H56:IC31 in HIV-
negative adults with
and without latent
tuberculosis (TB)
infection
|
PD-37
|
The Toll-like
Receptor 4 agonist adjuvant, GLA-
SE, improves
magnitude and quality of immune
responses elicited by
the ID93 tuberculosis vaccine
|
PD-36
|
Dose definition of
the novel TB vaccine
ID93+GLA-SE for TB
endemic countries
|
PD-39
|
Impact of
implementing an effective community
engagement strategy
on retention rates in a
Phase 2b Prevention
of Disease TB vaccine trial
in South Africa,
Zambia, and Kenya
|
OA-16
|
Immunogenicity and
efficacy evaluation of
prime-boost vaccine
regimens with ChAd3-4Ag
+/- MVA5Ag in rhesus
macaques
|
Breakout Session 3:
Novel Vaccine
Concepts and
Preclinical Research
Time: 11:30 – 13:00,
February 22
Location:
Shahjehan
|
OA-21
|
Evaluating immune
correlates of risk of
Mycobacteria
tuberculosis infection in humans
|
Breakout Session 4:
Biomarkers,
Correlates and
Epidemiology
Time: 11:30 – 13:00,
February 22
Location:
Jehangir
|
About Aeras
Aeras is a nonprofit organization advancing the development of
new tuberculosis vaccines for the world in partnership with other
biotech, pharmaceutical and academic organizations. Aeras is
primarily funded by The Bill & Melinda Gates Foundation, the UK
Department for International Development (DFID), and other parties
committed to ending the TB epidemic. Aeras also receives support
from the U.S. government and through partnerships and
collaborations with universities and pharmaceutical companies
around the world. Aeras is headquartered in Rockville, Maryland (USA), with a clinical
development and operations office in Cape
Town, South Africa. For more information, please visit
www.aeras.org.
Aeras is a lead organizing partner of the 5th Global
Forum on TB Vaccines.
For more information, contact:
Jennie Willson at
jwillson@aeras.org or +1 301-547-2840
View original
content:http://www.prnewswire.com/news-releases/aeras-highlights-commitment-to-eradicating-the-worlds-leading-infectious-disease-killer-at-the-5th-global-forum-on-tuberculosis-300600421.html
SOURCE Aeras